We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Best of the Best |

Top-Accessed Article: Basal Cell Nevus Syndrome FREE

Natalia Gomezospina, PhD; Anthony E. Oro, MD, PhD
[+] Author Affiliations

Author Affiliations: Program in Epithelial Biology, Stanford University School of Medicine, Stanford, California.

Arch Dermatol. 2011;147(10):1213. doi:10.1001/archdermatol.2011.304.
Text Size: A A A
Published online

Goldberg LH, Firoz BF, Weiss GJ, Blaydorn L, Jameson G, Von Hoff DD. Basal cell nevus syndrome: a brave new world. Arch Dermatol. 2010;146(1):17-19.

While most basal cell carcinomas (BCCs) are amenable to resection, surgical intervention is impractical for patients with metastatic or locally invasive BCCs or cancer predisposition syndromes, such as basal cell nevus syndrome. Until now, treatments for these nonsurgical candidates met with limited efficacy. The causal role of aberrant hedgehog signaling in BCCs has led to the recent exploration of hedgehog pathway inhibitors as a targeted therapy, and, as shown by Goldberg et al last year, the smoothened antagonist GDC-0449 [2-chloro-N- (4-chloro-3-[pyridin-2-yl]phenyl)-4-(methylsulfonyl)benzamide] can achieve clinical regression in basal cell nevus syndrome. Since Goldberg and colleagues' article was published, GDC-0449 has demonstrated efficacy against advanced BCCs and metastatic medulloblastoma, and hedgehog pathway inhibitors are currently under clinical investigation for several other lethal cancers. Hedgehog pathway inhibitors offer a new adjuvant medical therapy for advanced and, if trials demonstrate effectiveness, early-stage BCCs.

From August 2009, through August 2010, this article was viewed 1858 times on the Archives of Dermatology Web site.


Contact Dr Oro at Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305 (oro@stanford.edu).

Financial Disclosure: The authors have participated in a Genentech-sponsored trial for GDC-0449.

This article was corrected for errors on October 17, 2011.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.